ARK Genomic Last Dividend Paid vs. Price To Book
| ARKG Etf | USD 25.98 0.55 2.16% |
For ARK Genomic profitability analysis, we use financial ratios and fundamental drivers that measure the ability of ARK Genomic to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well ARK Genomic Revolution utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between ARK Genomic's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of ARK Genomic Revolution over time as well as its relative position and ranking within its peers.
ARK |
The market value of ARK Genomic Revolution is measured differently than its book value, which is the value of ARK that is recorded on the company's balance sheet. Investors also form their own opinion of ARK Genomic's value that differs from its market value or its book value, called intrinsic value, which is ARK Genomic's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ARK Genomic's market value can be influenced by many factors that don't directly affect ARK Genomic's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ARK Genomic's value and its price as these two are different measures arrived at by different means. Investors typically determine if ARK Genomic is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ARK Genomic's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
ARK Genomic Revolution Price To Book vs. Last Dividend Paid Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining ARK Genomic's current stock value. Our valuation model uses many indicators to compare ARK Genomic value to that of its competitors to determine the firm's financial worth. ARK Genomic Revolution is the top ETF in last dividend paid as compared to similar ETFs. It also is the top ETF in price to book as compared to similar ETFs fabricating about 3.09 of Price To Book per Last Dividend Paid. Comparative valuation analysis is a catch-all technique that is used if you cannot value ARK Genomic by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.ARK Price To Book vs. Last Dividend Paid
Last Dividend Paid refers to dividend per share(DPS) paid to the shareholder the last time dividends were issued by a company. In its conventional sense, dividends refer to the distribution of some of a company's net earnings or capital gains decided by the board of directors.
ARK Genomic |
| = | 1.05 |
Many stable companies today pay out dividends to their shareholders in the form of the income distribution, but high-growth firms rarely offer dividends because all of their earnings are reinvested back to the business.
Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.
ARK Genomic |
| = | 3.26 X |
Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.
ARK Price To Book Comparison
ARK Genomic is currently under evaluation in price to book as compared to similar ETFs.
ARK Genomic Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in ARK Genomic, profitability is also one of the essential criteria for including it into their portfolios because, without profit, ARK Genomic will eventually generate negative long term returns. The profitability progress is the general direction of ARK Genomic's change in net profit over the period of time. It can combine multiple indicators of ARK Genomic, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
The fund is an actively-managed exchange-traded fund that will invest under normal circumstances primarily in domestic and foreign equity securities of companies across multiple sectors, including healthcare, information technology, materials, energy and consumer discretionary, that are relevant to the funds investment theme of the genomics revolution . Ark Genomic is traded on BATS Exchange in the United States.
ARK Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on ARK Genomic. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of ARK Genomic position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the ARK Genomic's important profitability drivers and their relationship over time.
Use ARK Genomic in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ARK Genomic position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ARK Genomic will appreciate offsetting losses from the drop in the long position's value.ARK Genomic Pair Trading
ARK Genomic Revolution Pair Trading Analysis
The ability to find closely correlated positions to ARK Genomic could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ARK Genomic when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ARK Genomic - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ARK Genomic Revolution to buy it.
The correlation of ARK Genomic is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ARK Genomic moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ARK Genomic Revolution moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for ARK Genomic can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your ARK Genomic position
In addition to having ARK Genomic in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Government Funds Thematic Idea Now
Government Funds
Funds or Etfs that invest in fixed income securities issued by national government to finance government spending or to facilitate Federal Reserve monetary policies. The Government Funds theme has 42 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Government Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Trending Equities. You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
To fully project ARK Genomic's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of ARK Genomic Revolution at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include ARK Genomic's income statement, its balance sheet, and the statement of cash flows.